Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...
Le Lézard2h
Trimble receives expected delisting and deficiency notice from Nasdaq
at 06:50 Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. Merck , known as MSD outside of the United States and ...
Pharmabiz9h
Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million
Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...